BioMerieux has announced the launch of an innovative molecular biology platform for the extraction of nucleic acids, including DNA and RNA.
The eMAG system has received CE Mark approval and is debuting in Europe and the US, with a further programme to gradually roll the product out in other territories planned for early 2017.
“BioMerieux has launched eMAG, a new molecular biology platform for the extraction of nucleic acids.“
It is able to extract 48 samples in 90 minutes directly from a primary sample, with all sample types handled in a single series to allow laboratories to monitor patients efficiently.
Because it is highly automated, it offers greater traceability and effective throughput, in to unparalleled flexibility for an automated system of this kind. The system also incorporates cutting-edge BOOM technology for the extraction of DNA and RNA.
The eMAG system is designed for use with a broad variety of biological samples, including whole blood, plasma, serum, stool, respiratory samples and cerebrospinal fluid.
Randy Rasmussen, chief executive officer of BioFire Diagnostics and vice-president of molecular biology at BioMerieux, said: "The remarkable flexibility of eMAG, its high throughput, and the extraction performance illustrate our commitment to high-quality molecular solutions for the diagnosis of infectious diseases."
With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Science